FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207040284> ?p ?o ?g. }

• W4207040284 endingPage "e003853" @default.
• W4207040284 startingPage "e003853" @default.
• W4207040284 abstract "There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with advanced melanoma who have progressive disease after programmed death 1 (PD-1) blockade.We conducted a randomized multicenter phase II trial in patients with advanced melanoma. Patients were randomly assigned to receive either 1 mg/kg of nivolumab plus 3 mg/kg of ipilimumab or 3 mg/kg of ipilimumab every 3 weeks for up to four doses. Patients were stratified by histological subtype and prior response to PD-1 therapy. The primary clinical objective was overall response rate by week 18. Translational biomarker analyses were conducted in patients with blood and tissue samples.Objective responses were seen in 5 of 9 patients in the ipilimumab arm and 2 of 10 patients in the ipilimumab+nivolumab arm; disease control rates (DCRs) (66.7% vs 60.0%) and rates of grade 3-4 adverse events (56% vs 50%) were comparable between arms. In a pooled analysis, patients with clinical benefit (CB), defined as Response Evaluation Criteria in Solid Tumors response or progression-free for 6 months, showed increased circulating CD4+ T cells with higher polyfunctionality and interferon gamma production following treatment. Tumor profiling revealed enrichment of NRAS mutations and activation of transcriptional programs associated with innate and adaptive immunity in patients with CB.In patients with advanced melanoma that previously progressed on PD-1 blockade, objective responses were seen in both arms, with comparable DCRs. Findings from biomarker analyses provided hypothesis-generating signals for validation in future studies of larger patient cohorts.NCT02731729." @default.
• W4207040284 created "2022-01-26" @default.
• W4207040284 creator A5000768609 @default.
• W4207040284 creator A5002965160 @default.
• W4207040284 creator A5004706727 @default.
• W4207040284 creator A5011114578 @default.
• W4207040284 creator A5011325668 @default.
• W4207040284 creator A5015135453 @default.
• W4207040284 creator A5022333320 @default.
• W4207040284 creator A5040291209 @default.
• W4207040284 creator A5040663360 @default.
• W4207040284 creator A5049359065 @default.
• W4207040284 creator A5052205775 @default.
• W4207040284 creator A5052396441 @default.
• W4207040284 creator A5054656505 @default.
• W4207040284 creator A5060226333 @default.
• W4207040284 creator A5061090388 @default.
• W4207040284 creator A5066301151 @default.
• W4207040284 creator A5067420630 @default.
• W4207040284 creator A5083745558 @default.
• W4207040284 creator A5083883593 @default.
• W4207040284 creator A5088042471 @default.
• W4207040284 date "2022-01-01" @default.
• W4207040284 modified "2023-09-30" @default.
• W4207040284 title "Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses" @default.
• W4207040284 cites W1499291662 @default.
• W4207040284 cites W1538902372 @default.
• W4207040284 cites W1601626202 @default.
• W4207040284 cites W2019607817 @default.
• W4207040284 cites W2025890468 @default.
• W4207040284 cites W2029409133 @default.
• W4207040284 cites W2051452288 @default.
• W4207040284 cites W2080435444 @default.
• W4207040284 cites W2089536793 @default.
• W4207040284 cites W2097995306 @default.
• W4207040284 cites W2100634642 @default.
• W4207040284 cites W2112121482 @default.
• W4207040284 cites W2130410032 @default.
• W4207040284 cites W2130506153 @default.
• W4207040284 cites W2140875987 @default.
• W4207040284 cites W2144953100 @default.
• W4207040284 cites W2145871366 @default.
• W4207040284 cites W2162466652 @default.
• W4207040284 cites W2166180044 @default.
• W4207040284 cites W2169456326 @default.
• W4207040284 cites W2465860350 @default.
• W4207040284 cites W2572174216 @default.
• W4207040284 cites W2600132724 @default.
• W4207040284 cites W2742763599 @default.
• W4207040284 cites W2753432434 @default.
• W4207040284 cites W2761575992 @default.
• W4207040284 cites W2766877982 @default.
• W4207040284 cites W2779221466 @default.
• W4207040284 cites W2783897381 @default.
• W4207040284 cites W2794408630 @default.
• W4207040284 cites W2797675588 @default.
• W4207040284 cites W2800568511 @default.
• W4207040284 cites W2807819616 @default.
• W4207040284 cites W2808455729 @default.
• W4207040284 cites W2883970691 @default.
• W4207040284 cites W2909933152 @default.
• W4207040284 cites W2916647762 @default.
• W4207040284 cites W2943013004 @default.
• W4207040284 cites W2953744267 @default.
• W4207040284 cites W2959509555 @default.
• W4207040284 cites W2963476376 @default.
• W4207040284 cites W2981443129 @default.
• W4207040284 cites W2991341799 @default.
• W4207040284 cites W3003503441 @default.
• W4207040284 cites W3005411249 @default.
• W4207040284 cites W3032544449 @default.
• W4207040284 cites W3043703771 @default.
• W4207040284 cites W3083986479 @default.
• W4207040284 cites W3159504492 @default.
• W4207040284 cites W4254345745 @default.
• W4207040284 doi "https://doi.org/10.1136/jitc-2021-003853" @default.
• W4207040284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35074903" @default.
• W4207040284 hasPublicationYear "2022" @default.
• W4207040284 type Work @default.
• W4207040284 citedByCount "13" @default.
• W4207040284 countsByYear W42070402842022 @default.
• W4207040284 countsByYear W42070402842023 @default.
• W4207040284 crossrefType "journal-article" @default.
• W4207040284 hasAuthorship W4207040284A5000768609 @default.
• W4207040284 hasAuthorship W4207040284A5002965160 @default.
• W4207040284 hasAuthorship W4207040284A5004706727 @default.
• W4207040284 hasAuthorship W4207040284A5011114578 @default.
• W4207040284 hasAuthorship W4207040284A5011325668 @default.
• W4207040284 hasAuthorship W4207040284A5015135453 @default.
• W4207040284 hasAuthorship W4207040284A5022333320 @default.
• W4207040284 hasAuthorship W4207040284A5040291209 @default.
• W4207040284 hasAuthorship W4207040284A5040663360 @default.
• W4207040284 hasAuthorship W4207040284A5049359065 @default.
• W4207040284 hasAuthorship W4207040284A5052205775 @default.
• W4207040284 hasAuthorship W4207040284A5052396441 @default.
• W4207040284 hasAuthorship W4207040284A5054656505 @default.
• W4207040284 hasAuthorship W4207040284A5060226333 @default.
• W4207040284 hasAuthorship W4207040284A5061090388 @default.

• next